TTOP offers preclinical prediction services that replicate complex human pathophysiological conditions, providing more predictive results than conventional animal models. This approach minimizes controversial animal use in research while improving the accuracy of preclinical drug development.
Funding
Funding not disclosed
Founders
Product
Problem
The traditional drug development process is expensive and time-consuming, often requiring over $2 billion and 10-12 years to bring a new drug to market. Preclinical evaluations using conventional cell culture and animal models frequently fail to predict human responses accurately, leading to costly failures in clinical trials. Animal models also raise ethical concerns and may not fully translate to human physiology.
Solution
TTOP Technologies offers a modular microphysiological platform designed to replicate complex human pathophysiological conditions for more predictive preclinical testing. The platform utilizes a cartridge-based design suitable for both established cell seeding techniques and advanced culture methodologies, including 3D structures, scaffolds, and tissue biopsies. TTOP's technology enables compartmentalized co-cultures that mimic in-vivo local environments and allows for real-time imaging of biological samples. The platform facilitates easy retrieval of biological samples without morphological damage for post-treatment analysis and integrates with standard laboratory procedures and tools.
Target Audience
TTOP's primary customers are researchers and drug developers in the pharmaceutical and biotechnology industries seeking more predictive and physiologically relevant in-vitro models for preclinical drug testing.
Features
- Cartridge-based design compatible with various culture methodologies, including 3D structures and tissue biopsies.
- Modular design allowing integration with 12 or 24 well plates for conventional bicompartmental cultures.
- Compartmentalized co-cultures to replicate complex interactions between different cell types.
- Real-time imaging capabilities for monitoring cell growth, differentiation, and drug effects.
- Easy recovery of biological samples without damage for post-treatment analysis.
- Compatibility with standard Trans Epithelial Electrical Resistance (TEER) measurement devices and permeability assays.
- Perfusion modules with integrated micropumps for controlled apical and basolateral fluid flows.
- Integrated biosensors for real-time monitoring and control of experimental processes.